

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Zhi-Xing Yao et al.	Examiner:	Unknown
Serial No.:	10/663,619	Group Art Unit:	1614
Filed:	September 16, 2003	Docket:	1941.014US1
Title:	Neuroprotective Spirostenol Pharmaceutical Compositions		

---

**INFORMATION DISCLOSURE STATEMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications, and Non-Published Applications identifiable by USPTO Serial Number, are no longer required to be provided to the Office. Notification to this effect was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004 and October 19, 2004. Thus, Applicant has not included copies of any US Patents or US Patent Applications identifiable by serial number that may be cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

ZHI-XING YAO ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6905

Date June 27, 2006

By Monique M. Perdok Shonka  
Monique M. Perdok Shonka  
Reg. No. 42,989

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 27 day of June, 2006.

JUDY DENT  
Name \_\_\_\_\_

Signature \_\_\_\_\_

Judy Dent

Substitute for Form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Under the Patent Protection Act of 1990, in exchange for a copy of this document, a copy of this document is available to the public. If you are a U.S. citizen, a U.S. resident, or a U.S. corporation, a copy of this document is available to the public.

Complete if Known

<b>Application Number</b>	10/663,619
<b>Filing Date</b>	September 16, 2003
<b>First Named Inventor</b>	Yao, Zhi-Xing
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	Unknown

Sheet 1 of 1

Attorney Docket No: 1941.014US1

**US PATENT DOCUMENTS**

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date if Appropriate
	US-20060009433A1	01/12/2006	Yao, Z. , et al.	01/07/2005
	US-6,593,301	07/15/2003	Ma, B. , et al.	06/05/2000

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	DE-4303214A1	08/11/1994	Marks, W.	
	WO-0123408A1	04/05/2004	Barreclough, P. , et al.	
	WO-0211708A2	02/14/2004	Nieser, E. J. , et al.	
	WO-2006044685A2	04/27/2006	Yao, Z. , et al.	
	WO-9916786A1	04/08/1998	Ma, B. , et al.	
	WO-9948507A2	09/30/1999	Xia, Zongqin , et al.	

**OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BUNDGAARD, H. , "Design of Prodrugs", Elsevier Science Publishers, Chapter 1, (1985),1	
		KEEGAN, B. M. , et al., "Multiple Sclerosis", Annual Review of Medicine, 53, (2002),285-302	
		LECANU, LAURENT , "Identification of naturally occurring spirostenois preventing B-amyloid-induced neurotoxicity", Steroids, 69(1), (Jan., 2004),1-16	
		LI, H. , "Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steriodogenesis by an HIV TAT-CRAC peptide", Proceedings of the National Academy of Sciences, USA, (2001),98:1267-1272	
		ROHER, A E, , et al., "Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.", J. Biol. Chem., 268(5), (Feb. 15, 1993),3072-3083	
		SHOJI, M. , et al., "Distribution of amyloid beta protein precursor in the Alzheimer's disease brain", Psychiatry and Clinical Neurosciences, 54, (2000),45-54	
		YAO, ZHI-XING , et al., "22R-Hydroxycholesterol protects neuronal cells from beta-amyloid-induced cytotoxicity by binding to beta-amyloid peptide.", Journal of Neurochemistry, 83(5), (Dec., 2002),1110-1119	
		YAO, Z. X. , et al., "Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity", FASEB J., 16(12), (2002),1677-9	
		YOUNKIN, S. G. , "The role of A beta 42 in Alzheimer's disease.", J Physiol Paris, 92(3-4), (1998),289-292	

**EXAMINER**

**DATE CONSIDERED**

Information Disclosure Statement Form (PTO-1449)

\*EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 608. Only the three most recent references and not considered. Include copy of this form with next communication to applicant. If applicant's entire cited disclosure is new (unpublished) or applicant is to place a check mark here if English language translation is attached.